Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM WILL PARTICIPATE IN TWO HEALTHCARE CONFERENCES IN SEPTEMBER. NEUROPACE MANAGEMENT WILL HOST ONE-ON-ONE MEETINGS WITH INVESTORS AT THE WELLS FARGO 2025 HEALTHCARE CONFERENCE, ON WEDNESDAY, SEPTEMBER 3 IN BOSTON, MA. NEUROPACE MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT DISCUSSION AT THE CANTO.

NEUROPACE TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES

-- REPORTED RECORD QUARTERLY REVENUE OF $23.5 MILLION IN Q2 2025-- -- INCREASED FULL-YEAR 2025 REVENUE GUIDANCE TO BETWEEN $94 MILLION AND $98 MILLION AND GROSS MARGIN GUIDANCE TO BETWEEN 75% AND 76%-- -- REMAIN ON TRACK TO SUBMIT NAUTILUS DATA TO FDA FOR POTENTIAL IGE INDICATION EXPANSION IN THE SECOND HALF OF 2025 --CMS MAINTAINS CURRENT MS-DRG ASSIGNMENT FOR RNS SYSTEM PROCEDURES-- MOUNTAIN VIEW, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL DEVICE COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

NEUROPACE REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND INCREASES 2025 REVENUE GUIDANCE

MOUNTAIN VIEW, CALIF., AUG. 01, 2025 (GLOBE NEWSWIRE) -- NEUROPACE, INC. (NASDAQ: NPCE), A MEDICAL TECHNOLOGY COMPANY FOCUSED ON TRANSFORMING THE LIVES OF PEOPLE LIVING WITH EPILEPSY, TODAY ISSUED THE FOLLOWING STATEMENT IN RESPONSE TO THE CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) ELECTING NOT TO FINALIZE ITS PROPOSED REASSIGNMENT OF EPILEPSY WITH NEUROSTIMULATOR CASES IN THE FY 2026 INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS) RULE.

NeuroPace, Inc.

NPCE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NeuroPace, Inc.

NPCE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NPCE